|Day Low/High||141.41 / 146.04|
|52 Wk Low/High||90.14 / 176.64|
The list begins with oil, but there's a ripple effect.
The company lowered guidance for FY 2017, which is likely to blame for the company's fall.
Ackman launched a winning activist campaign at Chipotle last year.
The Mars-VCA deal is yet another sign that pet health is a robust business.
Zoetis shares were climbing off an earnings beat and raised 2016 guidance.
Jim Cramer says Zoetis, an animal health company, is well run.
Teeth, pets, video games, eating at home are evidence of strong theses.
Here's a window into what institutional investors may be doing and how to profit from that.
It may not be possible for Valeant to wind down its massive debt as quickly as expected, say Deutsche Bank analysts.
Zoetis is not averse to a little noise as investors, analysts take notice.
Shares of Valeant Pharmaceuticals were higher Monday on news that the company named a new CFO.
Valeant's new CFO Paul Herendeen is a 'solid' performer and a welcome addition to the beleaguered company, says Jim Cramer
Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.
A potential blockbuster drug deal is reportedly in the works.
The humanization of pets has sent spending soaring, which has some pet-related stock seeing major benefits.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
U.S. futures look to follow the rally by other world market as Nintendo shares soar.
CAT not going down on bearish news gets us closer to a bottom and buy recommendation.
The S&P 500 fell almost 7% in the third quarter, the worst showing in four years.
OIH's path of least resistance is down. And quick follow-ups on NKE, ZTS and FCX.
Grexit woes continue to depress prices, but SCOTUS helps hospitals.